Vliyanie kureniya na effektivnost' kardiovaskulyarnykh preparatov

  • Authors: Leonova M.V1
  • Affiliations:
    1. ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава РФ
  • Issue: Vol 15, No 1 (2013)
  • Pages: 50-55
  • Section: Articles
  • URL: https://journals.rcsi.science/2075-1753/article/view/93758
  • ID: 93758

Cite item

Full Text

About the authors

M. V Leonova

ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава РФ

References

  1. Мировая статистика здравоохранения. Женева. ВОЗ. 2007.
  2. Демографический ежегодник России. Статистический сборник. М., 2001.
  3. Систематический подход к отказу от курения. Материалы семинара. Американский международный союз здравоохранения. Агентство США по международному развитию при технической поддержке центров по контролю над заболеваниями и профилактике. США. М., 2002.
  4. William B, White. Smoking - related morbidity and mortality in the cardiovascular setting. Prev Cardiol 2007; 10 (2 Suppl. 1): 1–4.
  5. Campisi R, Сzernin J, Schoder H et al. Effects of long - term smoking on myocardial blood flow, coronary vasomotion and vasodilator capacity. Circulation 1998; 98: 119–25.
  6. Оганов Р.Г., Деев А.Д., Жуковский Г.С. и др. Влияние курения на смертность от хронических неинфекционных заболеваний, по результатам проспективного исследования. Профилактика заболеваний и укрепление здоровья. 1998; 3: 13–5.
  7. Wilhelmsen L. Coronary heart disease: epidemiology of smoking and intervention studies of smoking. Am Heart J 1988; 115: 242–9.
  8. Hankey G.J. Smoking and risk of stroke. J Cardiovasc Risk 1999; 6: 207–11.
  9. Лукина Ю.В. Лекарственные препараты и курение. Рацион. фармакотерапия в кардиологии. 2005; 1: 31–6.
  10. Сахарова Г.М., Чучалин А.Г. Лечение табачной зависимости. РМЖ. 2001; 9 (5): 168–73.
  11. Barry J, Mead K, Nabel E.G. Effect of smoking on the activity of ischemic heart disease. JAMA 1989; 261 (3): 398–402.
  12. Hanna S.T. Nicotin effect on cardiovascular system and ion channel. J Cardiovasc Pharmacol 2006; 47 (3): 348–58.
  13. Ambrose J.A., Barua R.S. The pathophysiology of cigarette smoking and cardiovascular disease. An update. J Am Coll Cardiol 2004; 43: 1731–7.
  14. Rahman M.M., Laher I. Structural and functional alteration of blood vessels caused by cigarette smoking: an overview of molecular mechanisms. Curr Vasc Pharmacol 2007; 5 (4): 276–92.
  15. Toda N, Toda H. Nitric oxide - mediated blood flow regulation as affected by smoking and nicotine. Eur J Pharmacol 2010; 649 (1–3): 1–13.
  16. Raupach T, Schäfer K, Konstantinides S, Andreas S. Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm. Eur Heart J 2006; 27 (4): 386–92.
  17. Hung L, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patient with coronary disease taking aspirin. Circulation 1995; 92: 2432–6.
  18. De Cesaris R, Raniery G, Filliti V et al. Cardiovascular effects of cigarette smoking. Br J Clin Pharmacol 1987; 24 (2): 173–8.
  19. Bang L.E., Buttenschon L, Kristensen K.S., Svedsen T.L. Do we undertreat hypertensive smokers? A comparison between smoking and non - smoking hypertensives. Circulation 1994; 90 (1): 248–53.
  20. Girerd X, Brunel P, Laurent S et al. Effects of beta - blockers on haemodynamics of the forearm after tobacco stimulation. Arch Mal Coeur Vaiss 1988; 81: 133–6.
  21. Miller L.G. Recent development in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics. Clin Pharmacokinet 1989; 17 (2): 90–108.
  22. Kimelski R. Interaction between smoking and drugs. Wiad Lek 1986; 39 (1): 31–4.
  23. Zevin S, Benowitz N.L. Drug interaction with tobacco smoking. An update. Clin Pharmacokinet 1999; 36 (6): 425–38.
  24. Renwick A.G., Le Vie J, Challenor V.F. et al. Factors affecting the pharmacokinetics of nifedipine. Eur J Clin Pharmacol 1987; 32 (4): 351–5.
  25. Berkan T, Mead K, Nabel E.G. Effect of smoking on the activity of ischemic heart disease. JAMA 1989; 261 (3): 398–402.
  26. Luczynska C, Wilson K. The clinical significance of the effects of cigarette smoking on drug disposition. Methods Find Exp Clin Pharmacol 1983; 5 (7): 479–87.
  27. Walle T, Walle U.K., Coward T.D. et al. Selektive induction of propranolol metabolism by smoking: additional affects on renal clearance of metabolites. J Рharmacol Exp Тher 1987; 241 (3): 928–33.
  28. Laustiola K.E., Lassila R, Kaprio J, Koskenvuo M. Decreased b - adrenergic receptor density and catecholamine response in male cigarette smokers. A study of monozygotic twin pairs discordant for smoking. Circulation 1988; 78 (Pt. 1): 1234–40.
  29. Laustiola K.E., Lassila R, Nurmi A.K. Enhanced activation of the renin - angiotensin - aldosterone system in chronic cigarette smokers: a study of monozygotic twin pairs discordant for smoking. Clin Pharmacol Ther 1988; 44 (4): 426–30.
  30. Leone A. Does Smoking Act as a Friend or Enemy of Blood Pressure? Let Release Pandora’s Box. Cardiology Research and Practice 2011; 1: 1–7.
  31. The ANBP management committee. The Australian therapeutic trial of mild hypertension. Lancet 1980; 1: 1261–7.
  32. Kotamaki M, Manninen V, Laustiola K.E. Enalapril versus atenolol in the treatment of hypertensive smokers. Eur J Clin Pharmacol 1993; 44 (1): 13–7.
  33. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97–104.
  34. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405–12.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies